For weight management purposes, B12 injections are not clinically indicated unless deficiency is documented
For weight management (NICE TA875 for semaglutide 2.4mg/Wegovy and TA664 for liraglutide 3mg/Saxenda): Treatment should be discontinued if specific weight loss targets are not met (typically at least 5% of initial body weight at 12-16 weeks)
For safety, also avoid alcohol for at least 24 hours after the injection, or longer if you received sedatives or prescription pain medicine
Research use only For qualified researchers
If a dose of a once-weekly GLP-1 medication is missed, patients should follow product-specific guidance
As a long-acting acylated islet amyloid polypeptide analog, the core application of Cagrilintide 5mg mainly focuses on the clinical management of obesity and type 2 diabetes, but its value is not limited to the core indications